Biohaven migraine drug partnered with Pfizer lands twin European approvals
Pfizer exited neuroscience drug research years ago, but the company still found a way to add a new neuro drug to its portfolio. An FDA-approved migraine drug from partner Biohaven Pharmaceuticals now has marketing authorizations in Europe, enabling the pharmaceutical giant to start capturing a share of the fast-growing product. The two companies announced Wednesday that the European Commission has approved Biohaven drug rimegepant for both migraine prevention and the treatment of acute migraine pain. The European decisions match the approved indications for the drug in the U.S., where it is marketed under the name Nurtec. In Europe, the drug will be called Vydura. The approvals in Europe are also a win for Pfizer. Last November, the pharma giant inked a deal for the right to commercialize rimegepant globally, with the exception of the U.S. where Biohaven retains rights. Pfizer paid $500 million up front, a combination cash and stock. It’s also on the hook to pay New Hav...